{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Rest+Product+1",
    "query": {
      "intervention": "Active Rest Product 1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Rest+Product+1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T18:12:46.572Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02947750",
      "title": "Neurovascular Transduction During Exercise in Chronic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic"
      ],
      "interventions": [
        {
          "name": "6R-BH4",
          "type": "DRUG"
        },
        {
          "name": "6R-BH4 placebo",
          "type": "OTHER"
        },
        {
          "name": "Folic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise training",
          "type": "OTHER"
        },
        {
          "name": "Stretching",
          "type": "OTHER"
        },
        {
          "name": "Histidine and beta-alanine supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Histidine and beta-alanine placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2016-10",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Decatur, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947750"
    },
    {
      "nct_id": "NCT07079761",
      "title": "Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",
          "type": "DRUG"
        },
        {
          "name": "Matching IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-08-04",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079761"
    },
    {
      "nct_id": "NCT02064387",
      "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "GSK2857916",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2014-07-29",
      "completion_date": "2019-08-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064387"
    },
    {
      "nct_id": "NCT01596907",
      "title": "Treatment of Low Metabolic Rate Following Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Morbid Obesity"
      ],
      "interventions": [
        {
          "name": "Ephedrine sulfate with caffeine",
          "type": "DRUG"
        },
        {
          "name": "cellulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Weight Loss Surgery, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 218,
      "start_date": "2012-05",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 2,
      "location_summary": "Beaverton, Oregon • Portland, Oregon",
      "locations": [
        {
          "city": "Beaverton",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596907"
    },
    {
      "nct_id": "NCT07593222",
      "title": "Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Major Depression",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Sham iTBS",
          "type": "DEVICE"
        },
        {
          "name": "TMS",
          "type": "DEVICE"
        },
        {
          "name": "D-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Dextromethophan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Mclean Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-09-01",
      "completion_date": "2031-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 1,
      "location_summary": "Belmont, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07593222"
    },
    {
      "nct_id": "NCT02102243",
      "title": "Neural Mechanism of Aldosterone-induced Insulin Resistance",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "DEFINITY® infusion",
          "type": "DRUG"
        },
        {
          "name": "Human Recombinant Regular Insulin infusion",
          "type": "DRUG"
        },
        {
          "name": "Dextrose infusion",
          "type": "DRUG"
        },
        {
          "name": "Flow mediated vasodilation",
          "type": "PROCEDURE"
        },
        {
          "name": "Endothelial cell collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Microvascular perfusion assessment using Definity",
          "type": "PROCEDURE"
        },
        {
          "name": "Microneurography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Wanpen Vongpatanasin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02102243"
    },
    {
      "nct_id": "NCT00960492",
      "title": "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Giant Cell Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "XL184",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-09",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960492"
    },
    {
      "nct_id": "NCT05657808",
      "title": "Radicle Rest 2: A Study of Health and Wellness Products on Sleep and Health Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep",
        "Sleep Disturbance",
        "Sleep Disorder"
      ],
      "interventions": [
        {
          "name": "Rest Study Active Product 1.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 1.2 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 2.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 2.2 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 2",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 3.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 4",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 4.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 4.2 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rest Study Active Product 4.3 Usage",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Radicle Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "105 Years",
        "sex": "ALL",
        "summary": "21 Years to 105 Years"
      },
      "enrollment_count": 4152,
      "start_date": "2023-01-09",
      "completion_date": "2024-04-15",
      "has_results": false,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 1,
      "location_summary": "Del Mar, California",
      "locations": [
        {
          "city": "Del Mar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05657808"
    },
    {
      "nct_id": "NCT01887678",
      "title": "Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Traumeel® / Zeel® Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biologische Heilmittel Heel GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 287,
      "start_date": "2013-06",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Dinuba",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01887678"
    },
    {
      "nct_id": "NCT01778218",
      "title": "A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Cell>Point LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-01",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-07-12",
      "last_synced_at": "2026-09-02T18:12:46.572Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01778218"
    }
  ]
}